Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bruce Booth sold 45,367 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $107.06, for a total value of $4,856,991.02. Following the sale, the director owned 466,077 shares of the company’s stock, valued at approximately $49,898,203.62. This trade represents a 8.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bruce Booth also recently made the following trade(s):
- On Friday, June 26th, Bruce Booth sold 467,878 shares of Kymera Therapeutics stock. The shares were sold at an average price of $110.29, for a total value of $51,602,264.62.
- On Monday, June 29th, Bruce Booth sold 31,283 shares of Kymera Therapeutics stock. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84.
- On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total value of $34,813,452.24.
- On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The stock was sold at an average price of $115.39, for a total value of $30,305,683.43.
- On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20.
- On Tuesday, June 23rd, Bruce Booth sold 1,408 shares of Kymera Therapeutics stock. The shares were sold at an average price of $99.98, for a total value of $140,771.84.
- On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total transaction of $24,268,431.60.
- On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total transaction of $10,471,246.56.
- On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total transaction of $9,496,316.98.
- On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.98, for a total transaction of $1,056,455.18.
Kymera Therapeutics Price Performance
KYMR traded up $5.35 on Tuesday, reaching $114.67. 1,134,754 shares of the company’s stock were exchanged, compared to its average volume of 766,343. The stock has a market cap of $9.43 billion, a PE ratio of -32.12 and a beta of 2.02. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The stock’s fifty day moving average price is $85.27 and its 200-day moving average price is $82.38.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on KYMR shares. Jefferies Financial Group initiated coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock. Stephens upped their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. B. Riley Financial boosted their price target on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the company a “buy” rating in a research report on Monday. Finally, Loop Capital set a $97.00 price objective on shares of Kymera Therapeutics in a report on Monday, June 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $121.41.
Read Our Latest Stock Report on KYMR
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in KYMR. Empowered Funds LLC purchased a new position in Kymera Therapeutics in the first quarter worth approximately $203,000. Glenmede Trust Co. NA raised its position in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares during the period. Amundi acquired a new position in shares of Kymera Therapeutics in the 1st quarter valued at $249,000. California State Teachers Retirement System lifted its stake in shares of Kymera Therapeutics by 23.0% in the 1st quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock valued at $4,688,000 after purchasing an additional 10,540 shares during the last quarter. Finally, Eagle Health Investments LP grew its holdings in shares of Kymera Therapeutics by 7.0% during the 1st quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock worth $12,145,000 after purchasing an additional 9,516 shares during the period.
Kymera Therapeutics Company Profile
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company’s pipeline emphasizes immunology and oncology.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
